Maria Faurholt-Jepsen1, Christian Ritz2, Mads Frost3, Rie Lambæk Mikkelsen4, Ellen Margrethe Christensen4, Jakob Bardram3, Maj Vinberg4, Lars Vedel Kessing4. 1. Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark. Electronic address: maria@faurholt-jepsen.dk. 2. Department of Basic Sciences and Environment, Faculty of Life Sciences, University of Copenhagen, Denmark. 3. The Pervasive Interaction Laboratory (PIT Lab), IT University of Copenhagen, Copenhagen, Denmark. 4. Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Abstract
BACKGROUND: A substantial proportion of patients with bipolar disorder remain symptomatic during inter-episode periods, and mood instability is associated with high risk of relapse and hospitalization. Few studies have investigated long-term daily illness activity and none has compared bipolar type I and II using daily data. The objectives were to investigate differences in daily illness activity between bipolar disorder type I and II. METHODS: A smartphone-based system for self-monitoring was developed. A total of 33 patients treated in a mood clinic used the system for daily self-monitoring during a median period of 310 days [IQR 189; 437]. Data presented summarize over 8500 observations. RESULTS: Patients with bipolar disorder type II (n=20), compared to patients with bipolar disorder type I (n=13), experienced a significant lower mean level of mood on a scale from -3; +3 (-0.54 (95% CI: -0.74; -0.35) versus -0.19 (95% CI: -0.35; -0.02), p=0.02), less time euthymic (51.0% (95% CI: 36.4; 65.7) versus 74.5% (95% CI: 62.4; 86.7), p=0.03) and a higher proportion of time with depressive symptoms (45.1% (95% CI: 30.6; 59.5) versus 18.8% (95% CI: 6.9; 30.7), p=0.01). The proportion of time spent with (hypo)manic symptoms did not differ (2.7% (95% CI: 0.1; 5.5) versus 5.5% (95% CI: 3.1; 7.8), p=0.17). LIMITATIONS: Patients received different types, doses and combinations of psychopharmacological treatment. CONCLUSION: Euthymia was obtained for a substantial proportion of time in patients with bipolar disorder type I, but despite on-going treatment only for half of the time for patients with bipolar disorder type II. This emphasizes the need for improving treatment strategies for bipolar disorder type II.
BACKGROUND: A substantial proportion of patients with bipolar disorder remain symptomatic during inter-episode periods, and mood instability is associated with high risk of relapse and hospitalization. Few studies have investigated long-term daily illness activity and none has compared bipolar type I and II using daily data. The objectives were to investigate differences in daily illness activity between bipolar disorder type I and II. METHODS: A smartphone-based system for self-monitoring was developed. A total of 33 patients treated in a mood clinic used the system for daily self-monitoring during a median period of 310 days [IQR 189; 437]. Data presented summarize over 8500 observations. RESULTS:Patients with bipolar disorder type II (n=20), compared to patients with bipolar disorder type I (n=13), experienced a significant lower mean level of mood on a scale from -3; +3 (-0.54 (95% CI: -0.74; -0.35) versus -0.19 (95% CI: -0.35; -0.02), p=0.02), less time euthymic (51.0% (95% CI: 36.4; 65.7) versus 74.5% (95% CI: 62.4; 86.7), p=0.03) and a higher proportion of time with depressive symptoms (45.1% (95% CI: 30.6; 59.5) versus 18.8% (95% CI: 6.9; 30.7), p=0.01). The proportion of time spent with (hypo)manic symptoms did not differ (2.7% (95% CI: 0.1; 5.5) versus 5.5% (95% CI: 3.1; 7.8), p=0.17). LIMITATIONS: Patients received different types, doses and combinations of psychopharmacological treatment. CONCLUSION: Euthymia was obtained for a substantial proportion of time in patients with bipolar disorder type I, but despite on-going treatment only for half of the time for patients with bipolar disorder type II. This emphasizes the need for improving treatment strategies for bipolar disorder type II.
Authors: Katie M White; Charlotte Williamson; Nicol Bergou; Carolin Oetzmann; Valeria de Angel; Faith Matcham; Claire Henderson; Matthew Hotopf Journal: NPJ Digit Med Date: 2022-06-29
Authors: Molly Patapoff; Marina Ramsey; Madison Titone; Christopher N Kaufmann; Atul Malhotra; Sonia Ancoli-Israel; David Wing; Ellen Lee; Lisa T Eyler Journal: J Psychiatr Res Date: 2022-04-03 Impact factor: 5.250
Authors: Marie-Camille Patoz; Diego Hidalgo-Mazzei; Bruno Pereira; Olivier Blanc; Ingrid de Chazeron; Andrea Murru; Norma Verdolini; Isabella Pacchiarotti; Eduard Vieta; Pierre-Michel Llorca; Ludovic Samalin Journal: Int J Bipolar Disord Date: 2021-06-03
Authors: Bernardo Dell'Osso; Saloni Shah; Dennis Do; Laura D Yuen; Farnaz Hooshmand; Po W Wang; Shefali Miller; Terence A Ketter Journal: Int J Bipolar Disord Date: 2017-01-25
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153
Authors: O Carr; K E A Saunders; A Tsanas; A C Bilderbeck; N Palmius; J R Geddes; R Foster; G M Goodwin; M De Vos Journal: Sci Rep Date: 2018-01-26 Impact factor: 4.379